Aurinia Pharmaceuticals Inc. current report, Q2 FY2016

Aurinia Pharmaceuticals Inc. - Form 6-K Summary

Business Context and Reporting Period

This Form 6-K was filed by Aurinia Pharmaceuticals Inc. on May 3, 2016. The filing serves to distribute materials related to the company's Annual General Meeting of Shareholders. The registrant is a Foreign Private Issuer filing under Form 40-F.

Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing containing notices and proxy materials rather than a financial results report.

Material Changes

No material changes to financial performance or operations are disclosed in this specific filing text.

Guidance, Outlook, and Risks

The filing does not contain management commentary, financial guidance, or specific risk disclosures. It includes an exhibit index listing the Notice of Annual General Meeting, Information Circular, and Form of Proxy.

Key Facts for Investors to Verify

  • Review the attached Information Circular (Exhibit 99.3) for detailed financial results and strategic updates.
  • Verify the date and agenda of the Annual General Meeting of Shareholders.
  • Confirm the company's status as a Foreign Private Issuer reporting under Form 40-F.